Karyopharm Therapeutics Inc（KPTI）資訊與事件KPTIKaryopharm Therapeutics Inc

Karyopharm Enters Forbearance Agreement with Creditors

In a regulatory filing, Karyopharm announced that the company and its subsidiary guarantors entered into a Forbearance Agreement and Limited Waiver to Indentures to provide the company with additional time to continue to advance its myelofibrosis program, further negotiate with its lenders, pursue strategic alternatives, or consummate an equity capital raise. The Forbearance Agreement is with (i) the lenders under the company's Credit and Guaranty Agreement, dated May 8, 2024, as amended, (ii) holders of 100% of the outstanding principal amount of the Company's 9.00% Convertible Senior Notes due 2028 (the "2028 Notes") issued under that certain Indenture, dated as of October 10, 2025 and 9.00% Convertible Senior Notes due 2029 issued under that certain Indenture, dated as of October 10, 2025, (iii) the investor representative under the company's Revenue Interest Financing Agreement, dated September 14, 2019, as amended, acting at the direction of the investors thereunder, and (iv) Wilmington Savings Fund Society, FSB, in its applicable agent and trustee capacities. The company did not pay the principal installment of approximately $15.8M due under the Credit Agreement on September 10, 2026 and does not expect to pay the cash interest due on September 30, 2026 under the Credit Agreement and the Indentures. Additionally, the company did not make cash interest payments on the Notes on June 30, 2026 and the Company may not satisfy the $25M minimum liquidity covenant that will apply under the Credit Agreement and the Indentures after October 10, 2026.

Karyopharm Submits sNDA for Accelerated Approval of XPOVIO

Karyopharm Therapeutics announced that it has submitted a supplemental New Drug Application, sNDA, to the U.S. Food and Drug Administration, FDA, seeking Accelerated Approval for XPOVIO in combination with ruxolitinib for patients with myelofibrosis. Karyopharm requested Priority Review of the application, which, if granted, could result in a six-month review process. "Today's submission is an important step toward our goal of bringing the combination of selinexor plus ruxolitinib to patients with myelofibrosis who continue to face a significant unmet need," said Reshma Rangwala, M.D., Ph.D., Chief Medical Officer and Head of Research of Karyopharm. "The SENTRY trial generated compelling and consistent results, including rapid, deep and sustained spleen responses across a broad range of patients, together with a promising overall survival signal and important evidence of disease modification. We believe the strength of these data underscores the potential of this novel combination to deliver meaningful long-term benefits and fundamentally change the treatment of patients with myelofibrosis."